Journal profile

Movement disorders : official journal of the Movement Disorder Society

Publisher: Wiley-Liss
ISSN0885-3185 | 0855-3185 | 1531-8257 FormatPrint StatusCurrently indexed

Journal Citation Impact

Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.

Impact Factor
4.22
Citation rate 5.58 4,151 total citations
h5-index 77 h5 depth signal
Cited share 71.4% 554 of 776
Total citations 4,151 Citation footprint
Metric signal 5.19 External metric anchor
Self-citation 6.2% 257 self-citations

Citations Trend

Monthly Publications Cadence

Citing Geographic Demographics

United States 1,457
Germany 743
United Kingdom 665
Canada 564
Italy 505

Citing Fields of Research

Neurodegenerative Disorders 3,080
Neurosciences 597
Postural Control 497
Migraines & Headaches 410
Brain Neurological Disorders 278

Publishing Activity & Reach

Volume, recency, access pattern, and citing-community signals from the journal analytics record.

All-time article footprint 13,218 Articles tracked across the journal lifetime
Indexed publication set 776 554 cited publications
Last 12 months 489 40.8 publications/month
Open access share 45.6% 223 OA publications in the last year
Leading citing country United States 1,457 citing publications
Leading citing field Neurodegenerative Disorders 3,080 citing publications
Latest tracked publication 19 October 2026 10 recent records available

Coverage & Indexing History

MEDLINE
v1n1, 1986-
PubMed
v1n1, 1986-
Index medicus
Active Coverage

Research Focus & Classification

Indexed Subjects

Neurodegenerative Disorders

Issuing & Sponsoring Bodies

Contributor
Movement Disorder Society

Broad Categories

Neurology Neurodegenerative Disorders

MeSH Descriptors

Movement Disorders

Latest Publications

Recent article records with DOI-first linking and condensed abstracts.

04
Mariagrazia Talarico, Andrea Quattrone, Giorgia Lucia Benedetto et al.
Background: Progressive supranuclear palsy (PSP) is a devastating 4‐repeat tauopathy with no approved disease‐modifying treatments. Recent evidence showed increased transforming growth factor‐β (TGF‐β) levels in PSP patient‐derived ventr...
08
Jesús Pérez-Pérez, Gonzalo Olmedo-Saura, Arnau Puig Davi et al.
Background: The Huntington's Disease Integrated Staging System (HD‐ISS) provides a framework for staging HD but does not incorporate fluid biomarkers. Objective: The aim of this study was to examine neurofilament light chain (NfL) and mu...

Bibliographical & Catalog Notes

Title from cover.

Supplements accompany some vols.

Vols. accompanied by videocassette supplements - videocassettes : sd., col.. ; 1/2 in.

Also issued online.

Vol. 3, no. 1 (1988)19900914 Notice not published Printed on acid-free paper